Compare AbbVie Inc (ABBV) vs Chart Industries Inc (GTLS) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

GTLS trades at $208.73 with minimal daily movement, showing technical bullish signals from moving averages while oscillators remain neutral. The company reported $4.26B revenue for 2025 but has missed earnings expectations for three consecutive quarters, with negative profit margins and elevated valuation ratios. Recent news highlights Baker Hughes' pending $13.6B acquisition and new supply agreements supporting future growth.

Investment outlook remains mixed with strong analyst buy consensus (54%) offset by recent earnings underperformance. Key opportunities include acquisition premium potential and operational scale, while risks center on profitability challenges and integration execution. The stock's valuation appears stretched given current negative returns on equity and assets.